New hub strengthens Teoxane’s commitment to scientific education and clinical partnerships across Asia-Pacific

GENEVA, Jan. 14, 2026 /PRNewswire/ — Teoxane opens its first APAC Regional Academy in Bangkok, Thailand this January, expanding its global medical-education network. Located on Level 12 of One Bangkok Tower 4, the hub offers a modern environment designed to support high-quality clinical training.

Purpose-built as a regional center of excellence, the Academy will upskill licensed aesthetic practitioners through science-based education, hands-on technique, and expert exchange, reinforcing Teoxane’s long-term collaboration with KOLs and clinicians across Asia-Pacific — one of the fastest-growing aesthetics markets.

“Asia-Pacific is one of the most dynamic aesthetics regions in the world. Opening our first APAC Regional Academy reflects our commitment and trust in the practitioners who shape the future of aesthetic medicine.” — Can Ongen, Chief Operating Officer

The Academy opened on 13 January, bringing Teoxane leadership and APAC regional partners together in Bangkok to mark the milestone. “Consumers across Asia now treat aesthetics as a lifestyle — prioritising skin quality, personalisation, and subtle refinement. The Academy helps practitioners meet those expectations with scientific precision.” — Krishna Sai, VP APAC

Advancing Education Across APAC

Developed with international experts, the Academy will deliver evidence-based curricula, including the MLT 3.1® injection approach and ATP™ methodology for personalised aesthetic assessment. Training formats include:
• Workshops
• Expert roundtables
• Regional symposia
• Live-learning and digital resources

Launching with Train-the-Trainer and Teoxane babyGLOW™

The first program introduces Teoxane’s latest innovation for skin quality – Teoxane babyGLOW™, led by Dr Silvia Caboni, one of the expert injectors behind the methodology. Following a soft launch in Spain (Q4 2025), early feedback from European practitioners and media has been strongly positive, highlighting not only strong science, but also treatment designed for modern lifestyles – fast, low-maintenance, comfortable, with an immediate glow and minimal downtime.

Raising Standards in APAC

The Academy will offer tailored development pathways to advance both the science and artistry of aesthetic practice, supported by Teoxane’s HA-based portfolio and two decades of scientific leadership.

This Academy allows us to deepen our mission: to elevate aesthetic practice through education that is rigorous, hands-on, and rooted in real-world clinical experience. By working closely with our regional experts, we can accompany practitioners throughout their entire learning journey — from foundational skills to advanced mastery.” — Dr. Mounia Heddad Masson, Director Global Medical Education & Medical Affairs

About Teoxane

Founded by Valérie Taupin in 2003, Teoxane specialises in developing solutions using hyaluronic acid. With over 20 years of expertise, Teoxane is a pioneer in the science of facial beauty. The company was founded on a unique vision: to open the possibilities of aesthetic treatments using high-performance dermal fillers, skin boosters and aesthetic skincare developed through in-depth scientific research. Through attentive listening, education and establishing the foundations for a safer industry, Teoxane has ushered in a new era in aesthetic medicine. Here, minor beauty procedures wield a significant impact on a patient’s self-image and overall well-being.

www.teoxane.com

SINGAPORE, Jan. 14, 2026 /PRNewswire/ — Rockwell Automation, Inc. (NYSE: ROK) published its 2025 Sustainability Report, which showcases how the company is bringing together technology and manufacturing for a more sustainable tomorrow.

“As both a manufacturer and a trusted partner to industrial companies around the world, Rockwell is uniquely positioned to lead the transformation of operations through innovation and sustainability,” said Blake Moret, Chairman and CEO, Rockwell Automation. “Our technologies help customers reduce energy use, minimize waste, and lower emissions while improving productivity and quality. From smart machines and digital twins to advanced motion control and cybersecurity, our solutions are enabling manufacturers to meet their sustainability goals without compromising performance.”

The report reflects how Rockwell’s sustainability strategy is embedded across the business, from how the company designs and innovates, to how the company sources, manufactures, and delivers solutions to customers. It’s built around three core focus areas: Environment, Social, and Governance.

• Environment: Advancing energy and emissions management, designing products for sustainability, and building a responsible supply chain.
• Social: Creating a culture that empowers our people, prioritizes safety, and invests in the future workforce.
• Governance: Demonstrating integrity in everything Rockwell does—from cybersecurity and product safety to enterprise risk and ethical leadership.

The company drives outcomes that extend across stakeholders:

• Sustainable Customers: Enabling customers to meet their own sustainability goals through scalable, intelligent solutions.
• Sustainable Company: Working relentlessly to make Rockwell’s operations and culture even more safe, efficient, and responsible.
• Sustainable Communities: Investing in the places where employees live and work, creating lasting impact through education, workforce development, and environmental stewardship.

Our actions are grounded in measurable progress:

• Setting science-based targets to help deliver on emissions reductions.
• Investing in adaptation and resilience, climate-proofing supply chains.
• Scaling digital and AI solutions that unlock efficiencies and improve risk visibility.

“These efforts are not about checking boxes. They’re about building a more resilient business and creating long-term value,” said Emmanuel Guilhamon, Vice President, Sustainability, Rockwell Automation. “Sustainability is a growth strategy, and this report is our way of showing how that strategy comes to life.”

Read Rockwell’s 2025 Sustainability Report.

About Rockwell Automation

Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 26,000 problem solvers dedicated to our customers in more than 100 countries as of fiscal year end 2025. To learn more about how we are bringing the Connected Enterprise® to life across industrial enterprises, visit www.rockwellautomation.com.

SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ — DNV, the independent global assurance and risk management provider, is partnering with Korean AI-driven blood and cancer diagnostics company Noul to certify their malaria diagnosis, blood cell morphology and cervical cancer testing solutions, under the European Union’s In Vitro Diagnostic Medical Device Regulation (IVDR).

The EU’s IVDR provides a regulatory basis for establishing the safety and effectiveness of new in-vitro diagnostic (IVD) devices. Most  IVD devices require a certificate of compliance with the IVDR to receive a CE mark that allows their sale in the EU. However, many other countries also recognize the CE mark as sufficient to market IVD devices, making IVDR compliance a gateway to global market access.

As an IVDR Notified Body, DNV will carry out certification on three Noul solutions: the miLab™ MAL cartridge for malaria diagnosis, miLab™ BCM cartridge for blood cell analysis and miLab™ CER cartridge for cervical cancer testing. The solutions are based on Noul’s innovative miLab™ point-of-care diagnostic platform. Combining integrated sample preparation, digital imaging and AI analysis, the miLab ensures consistently high-quality testing and efficient workflows in any setting – from state-of-the-art urban hospitals to remote rural clinics.

“Noul’s AI-powered diagnostic lab, miLab™, combines accuracy and efficiency, and healthcare bodies around the world are interested in how miLab can help them deliver better care. Timely certification against appropriate standards is essential to our global expansion plans. Working with DNV’s local team of medical device certification experts here in Korea will help us take a big step in those plans,” said Taehwan (TH) Kim, Chief Business Officer and Head of Europe Regional Office at Noul.

“The world needs innovative diagnostic solutions like Noul’s miLab to be delivered to market with full confidence in their safety and accuracy while minimizing unnecessary delays. As one of the top 5 notified bodies globally – and thanks to our global team of auditors, technical assessors and clinicians – DNV offers efficient certification with the flexibility to adjust to manufacturers timelines and business goals,” said Cecilie Gudesen Torp, Global Director Medical Services at DNV.

SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ — Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical’s production capabilities for its innovative oncology therapy, Alluminox^® platform-based photoimmunotherapy.

Under the agreement, LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supporting Rakuten Medical’s global clinical development and future commercialization.

Rakuten Medical’s proprietary photoimmunotherapy technology is designed to selectively target cells in solid tumors, by combining cell-targeting moieties, such as antibodies, with light-activatable agents, enabling focal and selective destruction of solid tumor cells upon light exposure.

In Japan, the therapy is approved for recurrent head and neck cancer, and its footprint has expanded steadily, through broader site adoption and sustained year–over–year growth in treatment numbers. In parallel, a global Phase 3 clinical trial is underway in the United States, Taiwan region and Japan, with plans to start treatment in Ukraine and Poland soon.

Rakuten Medical also plans to initiate a Phase 1 clinical trial in Japan for other solid tumors beyond head and neck cancer this year. These clinical and commercial dynamics are driving increased demand for Rakuten Medical’s bioconjugates.

LOTTE Biologics has been expanding its capabilities as a global contract development and manufacturing organization (CDMO), particularly in the field of monoclonal and multispecific antibodies, antibody-drug conjugates (ADCs), and advanced bioconjugation services. LOTTE Biologics will support the production of monoclonal antibody intermediates and their conjugates for Rakuten Medical’s programs, through its specialized ADC manufacturing facility at the Syracuse Bio Campus in New York. The facility is equipped with dedicated ADC production capabilities and advanced bioconjugation technologies, enabling the company to deliver high-quality manufacturing services while meeting global regulatory requirements and ensuring stable supply for customers worldwide.

About LOTTE Biologics

Founded in 2022 and headquartered in Seoul, South Korea, LOTTE Biologics operates integrated biologics facilities in the United States and South Korea. Through a unified Dual Hub Service model, LOTTE Biologics enhances supply security, supports manufacturing scalability, and maintains consistent quality standards across regions. LOTTE Biologics provides modular, phase-appropriate manufacturing solutions spanning preclinical through commercial stages, with proven capability in producing mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, and multispecific modalities.

At the Syracuse Bio Campus in New York, LOTTE Biologics delivers high-quality GMP drug substance manufacturing supported by more than 62 global regulatory approvals. The site offers 40,000 L of total capacity across eight 5,000 L stainless steel bioreactors and includes analytical and warehouse infrastructure. In addition, the company has expanded into Antibody-Drug Conjugates (ADCs) through strategic investment in onsite conjugation suites, enabling a streamlined, end-to-end pathway from biologic drug substance production to ADC manufacturing within a single campus.

In South Korea, LOTTE Biologics is constructing three advanced bio plants at the Songdo Bio Campus. With the first facility already underway and scheduled for operation in 2027, each plant will include eight 15,000 L stainless steel bioreactors for commercial production, supported by multiple 3,000 L bioreactors for clinical-scale needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity.

Guided by the vision “Possibilities Beyond Limits,” LOTTE Biologics is committed to serving as a long-term, trusted partner, supporting efficient scale-up, dependable manufacturing execution, and the continuous advancement of clients’ therapeutic programs. More information about LOTTE Biologics, please visit: www.lottebiologics.com 

About Rakuten Medical, Inc.

Rakuten Medical, Inc. is a global biotechnology company developing and commercializing its Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell killing. Rakuten Medical’s photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in five countries/regions, including the United States, where it is headquartered, Japan, Taiwan region, Switzerland and India. For more information, visit www.rakuten-med.com.

About the Alluminox® Platform

The Alluminox® platform is Rakuten Medical’s investigational technology that combines pharmaceuticals, medical devices, medical technology and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration, and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690 nm) to transiently activate the drug. Rakuten Medical’s preclinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical’s Alluminox platform-based photoimmunotherapy is investigational.

SINGAPORE, Jan. 14, 2026 /PRNewswire/ — North London Collegiate School (Singapore) has established itself as a leading British international school in Singapore – and aims to become a regional hub for musical excellence. The school’s newly launched Young Musicians Award, a competition open to instrumentalists aged 5 to 18 from across Asia, reflects a deeper institutional commitment: that artistic development is inseparable from academic rigour.

A School-Wide Philosophy, Not Just a Programme

At North London Collegiate School (Singapore), music is not a peripheral activity. It sits at the heart of the school’s approach to developing confident, disciplined, and creatively ambitious young people. The Young Musicians Award extends this philosophy beyond the school’s own student body, inviting young musicians from across the region to compete on a professional stage.

The competition received a strong regional response, with around 50 applicants shortlisted from across Asia. Finalists perform live in the school’s 700-seat auditorium – an environment designed to prepare young artists for the realities of professional performance.

Professional Opportunities and Recognition

The Young Musicians Award offers more than stage time. Through a partnership with Songwork International, finalists gain access to Singapore’s Lion Studios for professional recording sessions – an experience that introduces young musicians to industry-standard production environments typically encountered only at advanced levels of training.

Winners are invited to perform at a gala concert, while selected concerto finalists have the opportunity to perform alongside a symphony orchestra. A S$5,000 scholarship is awarded to one exceptional musician, representing a sustained investment in long-term artistic development.

International Standards, Delivered Locally

What further sets this initiative apart is the calibre of expertise behind it. The judging panel brings together leading figures from the international classical music world:

• Joshua Tan – Associate Conductor, Singapore Symphony Orchestra
• George Harliono – British concert pianist and Tchaikovsky Competition silver medallist
• Zhi Jong Wang – Professor of Violin, Shanghai Conservatory of Music

Their involvement reflects the global outlook that defines education at North London Collegiate School (Singapore), offering young musicians access to professional feedback typically reserved for conservatoire-level training.

Edward Jeffries, Head of Music (Senior School) at NLCS (Singapore) and founding lead of the Young Musicians Award, said: “The NLCS (Singapore) Young Musicians Award was conceived as a platform within Asia for young musicians to share their talent and celebrate their artistry. We are not a British International School that operates behind closed doors, but a community that seeks to champion excellence and provide our students and the wider community with opportunities to be inspired by exceptional young performers.

This competition is not intended solely for the benefit of our own students; rather, it aims to give a voice to young musicians from across the region. In doing so, it reflects our Music Department’s motto: “We Aspire to Inspire.”

Contributing to the Region’s Musical Landscape

By opening the competition to young musicians across Asia, North London Collegiate School (Singapore) is adding to the growing ecosystem of opportunities for classical music development in the region. The Young Musicians Award offers an accessible pathway for instrumentalists as young as five to experience professional performance settings, receive feedback from international adjudicators, and access studio recording – experiences that complement and strengthen the musical journeys young artists are already pursuing.

To learn more about the Young Musicians Award, visit: https://enquiries.nlcssingapore.com/young-musicians-award/

About North London Collegiate School (Singapore)

Founded in August 2020, North London Collegiate School (Singapore) is a British International School offering the academically ambitious NLCS curriculum, followed by the International Baccalaureate (IB) Middle Years Programme and culminating in the IB Diploma Programme.

Drawing on 175 years of educational heritage from its founding school in the UK, NLCS (Singapore) nurtures individuals to be intellectually curious, socially confident, and grounded in compassion through a rigorous academic framework, rich co-curricular opportunities, and exceptional pastoral care.

Situated on Depot Road, the School is part of a global family of schools committed to educational excellence and developing global citizens.

To learn more about NLCS (Singapore), please visit our website (https://nlcssingapore.sg/) and follow us on Instagram, Facebook, YouTube, and LinkedIn.

For media enquiries, please contact the NLCS (Singapore) Marketing Team
Email: marketing@nlcssingapore.sg

TAIPEI, Jan. 14, 2026 /PRNewswire/ — GIGABYTE unveils a new vision for how people engage with artificial intelligence at CES 2026, taking place from January 6 to January 9. Under the theme “The World as Prompt,” the company presents an immersive, AI-driven experience that brings together advanced laptop technologies, intelligent software, and human-centered interaction to explore new models of human-AI collaboration. 

Upon entering the experience, visitors generate a personalized AI digital twin that serves as a digital passport throughout the journey. This avatar connects participants to a series of interactive AI product experiences and ultimately generates a short mission highlight video as a personalized takeaway from their visit. 

Human-AI interaction comes to life through GIGABYTE RTX 50 series laptops and GiMATE, GIGABYTE’s smart AI Mate. Through natural voice-based interaction, GiMATE adapts to different usage scenarios, from creative work and coding to productivity and entertainment, demonstrating how AI can respond intuitively to individual needs and lifestyles. Real-time AI processing and on-device AI workloads enable responsive interaction without relying on cloud-based systems. 

The experience also offers a closer look at how hardware design supports next-generation AI performance. GIGABYTE’s WINDFORCE INFINITY EX thermal architecture allows visitors to visually explore the internal structure beneath the keyboard, illustrating how advanced cooling design helps sustain high-performance AI and GPU workloads. Newly introduced laptops, including the AERO X16 Copilot+ PC powered by AMD Ryzen™ AI 9 400 Series processors and NVIDIA^® RTX™ graphics, highlight GIGABYTE’s vision of portable AI computing designed to move seamlessly between work, play, and creativity. 

The journey culminates with the AORUS MASTER 16 (2026), showcasing refined lightweight design, premium materials, and the return of an OLED display with a high refresh rate for immersive gaming and creation. AI-enhanced workflows, including AI-assisted coding powered by GiMATE, demonstrate how performance and intelligence converge on a single platform. 

Through its CES 2026 experience, GIGABYTE illustrates a future where AI moves beyond automation to become a creative collaborator, responding not only to commands, but to human expression. Visitors can experience GIGABYTE’s Product Showcase at CES 2026, located at Venetian Expo, Level 3, Lido 3005.